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Shankar Thangamani, Waleed Younis & Mohamed N. Seleem
Novel antimicrobials and new approaches to developing them are urgently needed. Repurposing
already-approved drugs with well-characterized toxicology and pharmacology is a novel way to
reduce the time, cost, and risk associated with antibiotic innovation. Ebselen, an organoselenium
compound, is known to be clinically safe and has a well-known pharmacology profile. It has shown
potent bactericidal activity against multidrug-resistant clinical isolates of staphylococcus aureus,
including methicillin- and vancomycin-resistant S. aureus (MRSA and VRSA). We demonstrated that
ebselen acts through inhibition of protein synthesis and subsequently inhibited toxin production
in MRSA. Additionally, ebselen was remarkably active and significantly reduced established
staphylococcal biofilms. The therapeutic efficacy of ebselen was evaluated in a mouse model of
staphylococcal skin infections. Ebselen 1% and 2% significantly reduced the bacterial load and
the levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL6), interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1 (MCP-1) in MRSA USA300
skin lesions. Furthermore, it acts synergistically with traditional antimicrobials. This study provides
evidence that ebselen has great potential for topical treatment of MRSA skin infections and lays the
foundation for further analysis and development of ebselen as a potential treatment for multidrugresistant staphylococcal infections.

In 2013, the Centers for Disease Control and Prevention (CDC) reported that more than 11,000 people
died from a methicillin-resistant Staphylococcus aureus (MRSA)-related infection in the United States;
this figure represents nearly half of all fatalities caused by antibiotic-resistant bacteria. Apart from
the high mortality rate, S. aureus is the most common pathogen associated with skin and soft tissue
infections in humans1–4 . Furthermore, S. aureus and its secreted toxins, and ability to form biofilm,
are responsible for interfering with the wound-healing process and causing systemic complications in
affected patients. In addition, the rising prevalence of multidrug-resistant S. aureus strains and the extensive use of drugs of choice increase the likelihood that more challenging–to-treat isolates will become
a new scourge. Without a doubt, novel antimicrobials and novel approaches to developing them are
urgently needed; however, new antimicrobials are becoming increasingly difficult to develop and are
currently unable to keep pace with the emergence of resistant bacteria5. The concept of repurposing
drugs to find new applications outside the scope of their original medical indication is recently gaining
much attention and has resulted in successes in a number of disease areas6,7. Unlike de novo drug discovery, repurposing old drugs with known pharmacology and toxicology greatly reduces the time, cost,
and risk associated with antibiotic innovation7–9. In an attempt to repurpose non-antibiotic drugs as
antimicrobial agents, we screened National Institute of Health (NIH) Clinical Collection library against
MRSA6. Ebselen (2-phenyl-1, 2-benzisoselenazol-3(2H)-one, PZ51), a selenium-containing compound,
showed potent activity, in an applicable clinical range, against S. aureus, which is in agreement with the
previous finding10.
Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette,
Indiana, USA. Correspondence and requests for materials should be addressed to M.S. (email: mseleem@purdue.
edu)
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Strain type
Methicillin-resistant
S. aureus (MRSA)

Strain ID

eGenomics spa repeat
motiff

eGenomics
spatype

Ridom
spatype

Source

USA100

TJMBMDMGMK

Resistant to ciprofloxacin, clindamycin,
erythromycin

2

t002

United States (Ohio)

USA200

WGKAKAOMQQQ

Resistant to clindamycin, methicillin
erythromycin, gentamicin,

16

t018

United States (North Carolina)

USA300

YHGFMBQBLO

Resistant to erythromycin, methicillin,
tetracycline

2

t008

United States (Mississippi)

USA400

–

Resistant to methicillin, tetracycline

–

–

United States (North Dakota)

USA500

YHGCMBQBLO

Resistant to ciprofloxacin, clindamycin,
erythromycin, gentamicin, methicillin,
tetracycline, trimethoprim

7

t064

United States (Connecticut)

USA700

UJGFMGGM

Resistant to erythromycin, methicillin

49

t126

United States (Louisiana)

USA800

TJMBMDMGGMK

Resistant to methicillin

29

t088

United States (Washington)

USA1000

ZDGDGDEB

Resistant to erythromycin, methicillin

–

t316

United States (Vermont)

USA1100

–

Resistant to methicillin

–

–

United States (Alaska)

Phenotypic properties

ATCC 43300

–

Resistant to methicillin

–

–

United States (Kansas)

ATCC BAA–44

–

Multidrug–resistant strain

–

–

Lisbon, Portugal

Linezolid-resistant
S. aureus

NRS119 (Linr)

YHGCMBQBLO

Resistant to linezolid

7

t064

United States (Massachusetts)

Mupirocin-resistant
S. aureus

NRS 107

YHGGFMBQBLQ

Resistant to methicillin and mupirocin

59

t211

VRS1

TJMGMK

Resistant to vancomycin

–

t062

United States

VRS2

TJMBMDMGMK

Resistant to vancomycin, erythromycin,
spectinomycin

–

t002

United States

VRS3a

TJMBMDMGMK

Resistant to vancomycin

–

t002

United States

VRS3b

–

Resistant to vancomycin

–

–

United States

VRS4

TJMBMDMGMK

Resistant to vancomycin, erythromycin,
spectinomycin

–

t002

United States

VRS5

TJMBMDMGMK

Resistant to vancomycin

–

t002

United States

Vancomycin-resistant
S. aureus (VRSA)

S. epidermidis
S. aureus

VRS6

TJMGMK

Resistant to vancomycin

–

t062

United States

VRS7

TJMBMDMGMK

Resistant to vancomycin, β -lactams

–

t002

United States

VRS8

TJMBMDMGMK

Resistant to vancomycin

–

t002

United States

VRS9

TJMBMDMGMK

Resistant to vancomycin

–

t002

United States

VRS10

TJMBMDMGMK

Resistant to vancomycin

–

t002

United States

NRS101

–

Prototype biofilm producer; resistant to
methicillin, gentamicin

–

–

United States

ATCC 6538

–

Prototype biofilm producing strain

–

–

–

Table 1. Clinical isolates of Staphylococcus strains used in the study.

Previous studies reported that ebselen possesses anti- atherosclerotic, anti-inflammatory and antioxidative properties11–14. In addition, antimicrobial properties of ebselen has also been explored. It has been
shown to inhibit yeast and Escherichia coli in vitro10,15. It interferes with proton-translocation function
and ATPase activity in yeast, while in E. coli, it inhibits the thioredoxin reducatse (TrxR) enzyme15,16.
However, clinical applications and the underlying mechanism of action for its antibacterial activity
against S. aureus still remain unclear15.
Thus, the aim of our study is to assess the antibacterial action of ebselen and its spectrum of activity against clinical isolates of MRSA; to investigate its antimicrobial mechanism of action, anti-biofilm
activity, and effect on toxin production in MRSA; and finally to validate its antimicrobial efficacy,
anti-inflammatory properties, and potential clinical applications in MRSA infected animal model.

Results

Antibacterial activity of ebselen. The antimicrobial activity of ebselen was tested against a panel of
clinical isolates of multi-drug resistant S. aureus (Table 1). Ebselen showed potent bactericidal activity
against MRSA, vancomycin-resistant S. aureus (VRSA), linezolid-resistant S. aureus, mupirocin-resistant
S. aureus, methicillin-resistant S. epidermidis, and multidrug-resistant strains with a minimum inhibitory
concentration (MIC) ranging from 0.125 μ g/ml to 0. 5 μ g/ml (Table 2).
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Strain type
Methicillin resistant S. aureus (MRSA)

Strain ID

MICs (μg/ml)
Ebselen

Linezolid

USA100

0.125

2

Vancomycin
2

USA200

0.125

2

1

USA300

0.125

2

1

USA400

0.5

2

1

USA500

0.125

2

1

USA700

0.125

4

1

USA800

0.125

4

1

USA1000

0.125

2

1

USA1100

0.125

2

1

ATCC 43300

0.125

2

1

ATCC BAA-44

0.25

2

1

Linezolid-resistant S. aureus

NRS119

0.125

> 16

1

Mupirocin-resistant S. aureus

NRS 107

0.125

2

1

VRS1

0.25

1

> 16

VRS2

0.25

1

8
> 16

Vancomycin-resistant S. aureus (VRSA)

S. epidermidis
S. aureus

VRS3a

0.25

2

VRS3b

0.25

2

> 16

VRS4

0.125

2

> 16

VRS5

0.25

2

> 16

VRS6

0.25

2

> 16

VRS7

0.5

2

> 16

VRS8

0.125

2

> 16

VRS9

0.25

2

> 16

VRS10

0.25

2

> 16

NRS101

0.5

2

2

0.125

2

1

ATCC 6538

Table 2. MICs of ebselen and antibiotics against clinical isolates of Staphylococcus strains.

Mechanism of action. Given the potent anti-staphylococcal activity of ebselen in vitro, we investi-

gated its anti-staphylococcal mechanism of action by macromolecular synthesis assay. As shown in Fig. 1,
ebselen primarily inhibited protein synthesis at 1X the MIC. However, additional secondary effects were
observed at a higher concentration (8X MIC). At higher concentration, ebselen inhibited DNA, RNA and
lipid synthesis similar to control antibiotics such as ciprofloxacin, rifampicin and cerulenin respectively.

Ebselen inhibits MRSA toxin production. The effect of ebselen on production of important toxins

such as Panton-Valentine leucocidin (PVL) and α -hemolysin (Hla) was tested by ELISA. The concentrations of each toxin were compared as unadjusted concentrations (ng/ml) and corrected for organism
inoculum for each treatment (ng/ml to log10 colony-forming units, CFU/ml). Ebselen significantly suppressed toxin production in MRSA USA300 (Fig. 2).

Activity against biofilms. Considering the excellent broad-spectrum activity of ebselen against the
MRSA and VRSA strains, we also considered the possibility that ebselen would be active against established biofilm. Biofilm-forming strains of S. aureus and S. epidermidis were used and the biofilm mass
was estimated after treatment with ebselen and control antibiotics. Ebselen was significantly superior in
reducing adherent biofilms of both S. aureus and S. epidermidis when compared to conventional antibiotics (linezolid, mupirocin, vancomycin and rifampicin). Ebselen at (2 μ g/ml)(16X MIC) significantly
reduced the biofilm mass, approximately by 60%. Control antibiotics, such as linezolid (256 μ g/ml) (128X
MIC), mupirocin (16 μ g/ml) (128X MIC), and vancomycin (128 μ g/ml) (128X MIC), were able to reduce
the biofilm mass only by 20%. Rifampicin at 0.5 μ g/ml (16X MIC) reduced the biofilm mass by only 40%
(Fig. 3a).
Ebselen at 8 μ g/ml (16X MIC), significantly reduced the strong biofilms of S. epidermidis, by more than
50%. However, linezolid (512 μ g/ml) (256X MIC), mupirocin (32 μ g/ml) (256X MIC), and vancomycin
Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 1. Macromolecular synthesis in the presence of ebselen. Incorporation of radiolabeled precursors
of DNA, RNA, protein, cell wall and lipid synthesis ([3H] thymidine, [3H] uridine, [3H] leucine, [14C]
N-acetylglucosamine and [3H] glycerol, respectively) were quantified in S. aureus ATCC 29213. Results were
expressed as percent of inhibition calculated based on the incorporation of radiolabeled precursors.

(256 μ g/ml) (256X MIC) reduced biofilm mass by only 20% and rifampicin (2 μ g/ml) (64X MIC) reduced
biofilm mass by 40% (Fig. 3b).

Cytotoxicity study. Safety of ebselen in mammalian cells was evaluated against human keratinocyte
cells (HaCat) by MTS assay. Ebselen did not show toxicity up to 32 μ g/ml. The results demonstrated that
half maximal inhibitory concentration (IC50) required by ebselen to inhibit 50% of HaCat cells was found
to be 58.78 + 0.64 μ g/ml (Fig. 4).
The therapeutic efficacy of ebselen in a mouse model of MRSA skin infection.
(I) Bacterial load: Five groups of mice were treated topically either with vehicle alone (petroleum jelly)
or control antibiotic (2% mupirocin) or ebselen (0.5%, 1%, or 2%) twice a day for five days. One
group of mice was treated with linezolid orally. As shown in Fig. 5a, ebselen (1% and 2%) significantly reduced the mean bacterial counts compared with the control group (P ≤  0.01). The group
treated with 2% mupirocin had the highest reduction in CFU (2.28 ±  0.25 log10), followed by 2% ebselen (1.71 ±  0.11 log10), linezolid (25 mg/kg) (1.55 ±  0.01 log10), and 1% ebselen (1.02 ±  0.17 log10).
(II) Effect of vehicle: In order to investigate the effect of the vehicle on the efficacy of ebselen in the
treatment of MRSA skin infections, two groups of mice were treated topically either with vehicle
alone (lipoderm base)17 or ebselen 1% formulated in lipoderm base twice a day for five days. Ebselen
1% significantly reduced the mean bacterial counts by 1.37 ±  0.20 log10 compared with the control
group (P ≤  0.01) (Fig. 5b). Although ebselen formulated in lipoderm base had higher reduction in
bacterial count (1.37 ±  0.20 log10) than ebselen formulated in petroleum jelly (1.02 ±  0.17 log10), the
difference was not statistically significant (Fig. 5a,b).

Effect of ebselen on inflammatory cytokines induced by MRSA skin infection. To study the

immune-modulatory activities of ebselen in a topical application against MRSA skin infection, we used
ELISA to measure the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α ), interleukin-6 (IL6), interleukin-1 beta (IL-1β ) and monocyte chemo attractant protein-1(MCP-1) in the infected wounds.
As shown in Fig. 6, ebselen 2% and 1% significantly reduced all tested pro-inflammatory cytokines,
including IL-6, IL-1β , TNF-α , and MCP-1. However, ebselen at 0.5% significantly reduced IL-6 and
MCP-1 only. Ebselen had considerably higher anti-inflammatory activity compared to antibiotics (linezolid and mupirocin).

Synergistic activity of ebselen with topical antimicrobials in vitro.

The antimicrobial activity
of ebselen in combination with topical antimicrobials (mupirocin, fusidic acid, retapamulin and daptomycin) was investigated in vitro by the Bliss model of synergism against four clinical isolates. With the
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Figure 2. Effect of ebselen on toxin production. Toxin production (ng/ml) in S. aureus MRSA USA300
after antibiotic/drug exposure for 1 hour corrected for organism burden. The results are given as means ±  SD
(n =  3). **indicate statistical significant different from control (DMSO or water). P values of (*P ≤  0.05)
(**P ≤  0.01) are considered as significant. Detailed P values are listed: α Hemolysin: Control vs linezolid,
0.0144; Control vs ebselen, 0.0147. PVs-LK: Control vs linezolid, 0.0024; Control vs ebselen, 0.0288.

exception of the VRSA5 strain and the antibiotic daptomycin, ebselen acted synergistically with all tested
antibiotics against S. aureus clinical isolates (Fig. 7).

Discussion

For the past few decades the rise of multi-drug resistant S. aureus has been an emerging issue in hospital and community settings5,18. More importantly, the management of S. aureus strains associated with
skin infections is becoming a serious issue in community settings19,20. Although there are several drugs
recently approved by the FDA to combat Gram-positive pathogens such as tedizolid and dalbavancin21,22,
there is still a pressing need for new antimicrobials to circumvent this burgeoning problem. Moreover,
pharmaceutical companies are not interested in investing in antibiotic research and development because
of low return compared to other drugs being developed for chronic ailments5,23,24. As an alternative to
the traditional de novo antibiotic development, repurposing non-antimicrobial drugs is a novel and less
expensive way to speed up the drug-development process7.
In an intensive search for antimicrobial activity among non-antibiotic drugs, we and others10,15 identified ebselen as a potent antimicrobial agent against Gram-positive pathogens including MRSA. Ebselen,
an organoselenium compound, is known to be clinically safe with a well-known pharmacology profile
Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 3. The effects of ebselen and antibiotics (linezolid, mupirocin, vancomycin and rifampicin)
on established biofilms of S. aureus (a) or S. epidermidis (b). The established biofilms were treated with
control antibiotics or ebselen and stained with crystal violet. Optical density of dissolved crystal violet was
measured using a spectrophotometer. Values are the mean of triplicate samples with the standard deviation
bars. P values of (*,#P ≤  0.05) are considered as significant. Ebselen was compared to controls (*) and to
antibiotics (#). Detailed P values are listed: S. aureus (a): Control vs linezolid, 0.0214; Control vs mupirocin,
0.0001; Control vs vancomycin, 0.004; Control vs rifampicin, 0.0001; Control vs ebselen, 0.0001; linezolid vs
ebselen, 0.0014; mupirocin vs ebselen, 0.0004; vancomycin vs ebselen, 0.003; rifampicin vs ebselen, 0.0047. S.
epidermidis (b): Control vs linezolid, 0.0036; Control vs mupirocin, 0.0008; Control vs vancomycin, 0.0011;
Control vs rifampicin, 0.0004; Control vs ebselen, 0.0004; linezolid vs ebselen, 0.0033; mupirocin vs ebselen,
0.0052; vancomycin vs ebselen, 0.0040; rifampicin vs ebselen, n.s (not significant).

and it is currently undergoing clinical trials for the prevention and treatment of various disorders such
as cardiovascular disease, arthritis, stroke, atherosclerosis, and cancer12,25–28. Ebselen showed potent bactericidal activity against multiple clinical isolates of MRSA, including MRSA USA100, USA200, USA500,
USA1000, and USA1100, which are resistant to various antimicrobials, including penicillin, fluoroquinolone, macrolides, and aminoglycosides. It also showed potent activity against multidrug-resistant
clinical isolates of S. aureus strains, including a linezolid-resistant strain (NRS119), vancomycin-resistant
strains (VRSA1-VRSA10), and a mupirocin-resistant strain (NRS107). Moreover, ebselen demonstrated
excellent activity against MRSA USA300, a community-associated strain responsible for outbreaks of
staphylococcal skin and soft-tissue infections (SSTI) in the United States29.
Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 4. Cytotoxicity assay in human keratinocyte (HaCat) cells. HaCat cells were treated with different
concentration of ebselen ranging from 0 to 128 μ g/ml. DMSO was used as a negative control. Cell viability
was measured by MTS assay and IC50 of ebselen to cause cytotoxicity in HaCat cells was calculated.

Although the antimicrobial activity of ebselen has been reported before10,15, its mechanism of action
in S. aureus and its in vivo efficacy have never been explored. Ebselen, in our study, inhibited protein
synthesis in S. aureus. Inhibition of protein synthesis at a concentration equivalent to the MIC demonstrates that, protein synthesis is likely primary antibacterial mechanism of action of ebselen. In addition,
secondary effects on DNA, RNA, lipid synthesis and to a lesser extent on cell wall synthesis were also
noticed at higher concentrations (8X MIC). It is possible that disruption of protein synthesis could lead
to downstream inhibition of other pathways. This provides valuable insight into ebselen’s potential target
in S. aureus. However, further work is needed to identify the cellular target of ebselen in S. aureus. For
treatment of infections caused by toxin-producing pathogens such as S. aureus, inhibition of protein
synthesis is an important consideration in the selection of antimicrobial agents30. Because antimicrobials
that suppress translation in S. aureus markedly suppress the formation of toxins such as PVL and Hla,
which will lead to better treatment outcomes30–33. In the light of our results, showing potent inhibition
of bacterial protein synthesis, we tested the effect of ebselen on production of two important toxins in
MRSA USA300 (Hla and PVL) by ELISA. Ebselen significantly suppressed toxin production after 1 hour
incubation with MRSA. Inhibition of protein synthesis and the subsequent inhibition of toxin production
are great advantages of ebselen as an antimicrobial agent.
Bacterial biofilms, which serve to protect the bacteria and hinder penetration of antibacterial drugs,
contribute significantly to the treatment failure of Staphylococcus infections34. Given the potent antibacterial activity of ebselen against planktonic multidrug-resistant strains, we also considered the possibility
that ebselen would be active against established bacterial biofilms of S. aureus and S. epidermidis (a
leading cause of hospital-acquired implant-based infections)35. Ebselen was superior in reducing adherent biofilms of both S. aureus and S. epidermidis when compared to conventional antibiotics (linezolid,
mupirocin, vancomycin and rifampicin).
In view of our results demonstrating the potent antimicrobial and antibiofilm activities of ebselen
in vitro against MRSA, we moved forward with an in vivo experiment in a mouse model of MRSA
skin infection. Ebselen 1% and 2% in petroleum jelly significantly reduced the mean bacterial counts
compared with the control group (P ≤  0.01). The lipoderm base enhanced the antimicrobial activity of
ebselen but the reduction in bacterial load was not significant from petroleum jelly vehicle.
Since the clinical severity of S. aureus skin infections is driven by the excess host pro-inflammatory
cytokines rather than by bacterial burden36,37, ebselen with its recognized immune-modulatory,
anti-inflammatory, and antioxidant activities11,38 has great potential for treatment of for treatment of
skin infections37,39. In this study, topical treatment with ebselen 1 and 2% significantly reduced IL-1β ,
IL-6, TNF-α and MCP-1 which might benefit the healing of infected wounds40–44. Linezolid also inhibits
IL-1β which is in line with previous findings37,45. Prolonged inflammation especially due to inflammatory cytokines such as IL-6, TNF-α , and MCP-1, greatly delays healing in chronic wounds39. Ebselen
significantly (P ≤  0.01) inhibits all three cytokines (IL-6, TNF-α , and MCP-1), which should provide a
favorable outcome in wound healing39.
With the increasing incidence of MRSA strains resistant to topical drugs of choice, such as mupirocin and fusidic acid, combination therapies are being explored46–49. To investigate whether ebselen has
the potential to act synergistically with topical antimicrobials against multidrug-resistant strains, the
Bliss independence model was utilized50. Ebselen acted synergistically with topical antimicrobials against
resistant strains of S. aureus, thus providing a strong platform to combine ebselen with topical antimicrobials in treating staphylococcal skin infections and reducing the likelihood of strains developing
resistance to monotherapy.
Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 5. Efficacy of treatment of MRSA skin lesions with ebselen 0.5, 1, and 2%, linezolid (25 mg/kg),
mupirocin (2%) and petroleum jelly (negative control) twice daily for 5 days (a). Treatment with ebselen
1% and lipoderm (negative control) twice daily for 5 days (b). Statistical analysis was calculated by the twotailed Student t test. P values of (*P ≤0.05) (**P ≤0.01) are considered as significant. (#). Detailed P values
are listed: (a): Control vs 2% linezolid, 0.0038; Control vs 2% mupirocin, 0.0020; Control vs 1% ebselen,
0.0337; Control vs 2% ebselen, 0.0032. (b): Control vs 1% ebselen, 0.0280.

As a novel drug candidate for treating topical MRSA infections, ebselen has many advantageous
qualities, including (i) potent antibacterial activity against clinical isolates of MRSA irrespective of the
resistant patterns, (ii) suppression of bacterial protein synthesis and suppression of toxin production, (iii)
potent anti-biofilm activity, (iv) suppression of excess pro-inflammatory cytokines, and (v) synergistic
action with topical antimicrobials. These results lay the foundation for further analysis and development
of ebselen as a potential treatment/prophylaxis for infected wounds and skin infections of public-health
importance.

Materials and Methods

Bacterial strains and reagents. Staphylococcus strains used in this study are presented in Table 1.

Mueller-Hinton broth (MHB) was purchased from Sigma-Aldrich. Trypticase soy broth (TSB), Trypticase
soy agar (TSA), and Mannitol salt agar (MSA) were purchased from Becton, Dickinson (Cockeysville,
MD). Ebselen was purchased from (Adipogen corp, San Diego), vancomycin hydrochloride (Gold
Biotechnology), linezolid (Selleck Chemicals), mupirocin (applichem, NE), and chloramphenicol
(Sigma-Aldrich)

Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 6. Effect of ebselen on cytokines production in MRSA skin lesions. Supernatants from skin
homogenates were used for cytokine detection by ELISA. Each points represents single mice and each group
has 5 mice. Statistical analysis was calculated by the two-tailed Student t test. P values of (*P ≤0.05)
(**P ≤  0.01) are considered as significant. Detailed P values are listed: IL-1β : Control vs 2% linezolid, 0.0054;
Control vs 1% ebselen, 0.0026; Control vs 2% ebselen, 0.0007. IL-6: Control vs 0.5% ebselen, 0.0011; Control
vs 1% ebselen, 0.0055; Control vs 2% ebselen, 0.0006. TNF-α : Control vs 1% ebselen, 0.0424; Control vs
2% ebselen, 0.0164. MCP-1: Control vs 0.5% ebselen, 0.0004; Control vs 1% ebselen, 0.0325; Control vs 2%
ebselen, 0.0001.

Antibacterial assays. MICs of drugs and antibiotics were evaluated by broth micro dilution method
in MHB according to the Clinical and Laboratory Standards Institute (CLSI)34. The MIC was interpreted
as the lowest concentration of the drug that completely inhibited the visible growth of bacteria after
incubating plates for at least 16 hrs at 37 °C. Each drug was tested in triplicate in at least two independent
experiments and the highest MIC value was reported.
Macromolecular synthesis assay. Macromolecular synthesis assay was carried out in S. aureus
strain ATCC 29213. Briefly, 100 μ l of S. aureus grown in TSB at exponential phase (OD600 =  0.2 to
0.3), was added to triplicate wells and different concentrations of ebselen and control antibiotics (ciprofloxacin, rifampicin, linezolid, vancomycin and cerulenin) was added. DMSO treated cells served as a
negative control. Cells treated with drugs and DMSO were incubated at 37 °C to allow the drug to act
Scientific Reports | 5:11596 | DOI: 10.1038/srep11596
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Figure 7. Synergistic activity of ebselen with topical antimicrobials. The Bliss Model for Synergy confirms
a synergistic effect, between ebselen and topical antimicrobials (mupirocin, fusidic acid, retapamulin
and daptomycin) against various resistant strains of S. aureus. Degree of synergy was quantified after
12 h of treatment with ebselen (0.0312 μ g/ml) in combination with sub-inhibitory concentrations of
topical antimicrobials. (Circle) daptomycin +  ebselen, (Square) retapamulin +  ebselen, (Triangle) fusidic
acid +  ebselen and (Inverted triangle) mupirocin + ebselen.

on bacterial cells. After 30 min incubation, radio labeled precursors for DNA, RNA, protein, cell wall
and lipid synthesis such as [3H] thymidine (0 5μ Ci), [3H] uridine (0.5 μ Ci), [3H] leucine (1.0 μ Ci), [14C]
N-acetylglucosamine (0.4 μ Ci), [3H] glycerol (0.5 μ Ci), respectively, were added for each reaction. After
15 min, reactions of DNA and RNA synthesis were stopped using 12 μ l of 5% trichloroacetic acid (TCA).
Similarly, protein synthesis was stopped after 40 min using 12 μ l of 5% TCA. Reaction wells containing
cell wall and lipid synthesis were stopped after 40 min using 100 μ l of 8% SDS and 375 μ l of chloroform/
methanol (1:2) respectively. Reactions (DNA, RNA and protein) were incubated on ice for 30 min and the
TCA precipitated materials were collected on a 25 mm GF/1.2 μ M PES 96 well filter plate. After washing
five times with cold 5% TCA, the filters were dried and counted using a Packard Top Count microplate
scintillation counter. For cell wall synthesis, reaction tubes were then heated at 95 °C for 30 min, cooled,
centrifuged, and spotted onto nitrocellulose membrane filters (0.8 μ M). After washing three times with
0.1% SDS, the filters were rinsed two times with deionized water, allowed to dry, and then counted using
a Beckman LS3801liquid scintillation counter. For lipid synthesis, reactions tubes were centrifuged at
13,000 rpm in a microfuge for 10 min, and then 150 μ l of the organic phase was transferred to a scintillation vial and allowed to dry for at least 1 hour. Samples were then counted using liquid scintillation
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counting. Based on the incorporation of radiolabeled precursors of DNA, RNA, protein, cell wall and
lipid synthesis, results were expressed as percent inhibition of macromolecular synthesis pathways.

Measuring toxin production by ELISA.

We tested the effect of ebselen on production of two important toxins Hla and PVL by ELISA as described before30,51. Briefly, Overnight grown MRSA USA300
bacterial culture was diluted approximately to 5 ×  108 CFU/ml in TSB. 10X MICs of drugs and antibiotics
were added and incubated in the shaking incubator at 37 °C. After 1 hr the bacterial culture was centrifuged and the supernatants were used for toxin detection.
ELISA plates (Nunc) were coated with 2 μ g/ml of sheep anti-Hla IgG (Toxin technology) in 100 μ l
of coating buffer and left overnight at 4 °C. Plates were then washed 3 times with Tris-buffered saline
(TBS) containing 0.05% tween 20 (wash buffer) and then blocking solution containing TBS with 2%
bovine serum albumin was added. After 1 hour incubation at 37 °C, plates were washed 3 times with
wash buffer. A total of 100 μ L of bacterial supernatants were added and incubated the plates at 37 °C
for 2 hours. Purified Hla (Toxin technology) was used to generate a standard curve. Plates were again
washed 3 times with wash buffer and 100 μ L of sheep anti-Hla HRP conjugate at a dilution of 1:300 was
added. After 1 hour of incubation at 37 °C and final washing, 100 μ L of 3, 3′ , 5, 5′ -tetramethylbenzidine
substrate (Sigma-Aldrich) was added, and the reaction was stopped after 10 minutes with 100 μ L of 0.2N
H2S04. Plates were read on a spectrophotometer at optical density (OD) 450, and data were analyzed
with SoftMax Pro (Molecular Devices). The nominal range of this assay was 0.1–6 μ g /mL.
For PVL Luk-S toxin, ELISA plates (Nunc) were coated as before with 2 μ g /ml of mouse anti- PVL
Luk-S monoclonal antibody (IBT Bioservices). Purified S. aureus LukS-PV (His-tag) (IBT Bioservices)
was used to generate a standard curve. The experiment was carried as before except detection antibodies
rabbit anti-PVL Luk-S (2 μ g/ml) and rabbit IgG HRP conjugate (R&D Systems) at a dilution of 1:6000
was used. The concentrations of each toxin was compared as unadjusted concentrations (ng/ml) and
corrected for organism inoculum for each treatment (ng/ml to log10 CFU/ml).

Biofilm assay.

Biofilm assay was performed as described before34. Briefly, biofilm-forming clinical isolates of S. aureus (ATCC 6538) and S. epidermidis (ATCC 35984) were inoculated in 96-well flat-bottom
cell culture plates (polystyrene) in TSB supplemented with 1% glucose at 37 °C for 24 h. Then culture
medium was removed, and wells were carefully washed with PBS four times to remove planktonic bacteria. Ebselen and antibiotics (linezolid, mupirocin, vancomycin and rifampicin) were added at different
concentrations in TSB, and plates were incubated at 37 °C for 24 h. The wells were rinsed by submerging
the entire plate in a tub containing tap water. Biofilms were stained with 0.1% (wt/vol) crystal violet for
30 min. After staining, the dye was removed and the wells were washed four times with water. The plates
were dried for 1 h and ethanol (95%) was added to solubilize the dye bound to the biofilm. The OD of
biofilm mass was measured at 595-nm absorbance by using a micro plate reader (Bio-Tek Instruments
Inc.)

Cytotoxicity assay.

Human keratinocyte (HaCat) cells were seeded at a density of 10,000 cells per
well in a 96-well tissue culture plate (CytoOne, CC7682-7596) in DMEM media containing 10% fetal
bovine serum (FBS) and incubated overnight at 37 °C. Then cells were treated with ebselen at different
concentrations from 0 to 128 μ g/ml for 24 hours. Treated cells were washed four times with PBS and
the DMEM media containing MTS assay reagent, 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was added. After 4 hrs of incubation at 37 °C, absorbance was measured using ELISA microplate reader (Molecular Devices, Sunnyvale,
CA, USA). Percent cell viability of ebselen treated cells were calculated in relative to the untreated cells.

Mice infection. All experiments were performed in accordance with relevant guidelines and regulations. Eight weeks old female BALB/c mice were used for this study (Harlan Laboratories, Indianapolis,
IN). All animal procedures were approved by Purdue University Animal Care and Use Committee
(PACUC). The murine model of MRSA skin infection has been described before52. Mice were injected
intradermally with 40 μ l of MRSA USA300 (1.65 ×  108) CFU per mouse. Forty-eight hours after infection and formation of open wound, the mice were divided into eight groups (n =  5). Four groups were
treated topically with either 0.5%, 1%, or 2% ebselen in petroleum jelly (ointment- skin protectant) or
1% ebselen in lipoderm (dermal and transdermal delivery cream base). Two groups received the vehicles
alone (petroleum jelly or lipoderm). One group was treated topically with 2% mupirocin in petroleum
jelly and the last group was treated orally with linezolid (25 mg/kg). All groups were treated twice a day
for 5 days. Twenty-four hours after the last treatment, the area around the wound was lightly swabbed
with 70% ethanol and the wound was excised for bacterial counting on MSA after homogenization.
Cytokines detection. Skin homogenates were centrifuged and the supernatants were used to detect

the cytokine level by ELISA. Tumor necrosis factor-α (TNF-α ), interleukin-6 (IL-6), interleukin-1 beta
(IL-1β ), and monocyte chemo attractant protein-1(MCP-1) Duo-set ELISA Kits (R&D Systems, Inc.)
were used for the quantification of cytokines The experiment was carried out as per the manufacture
instructions53.
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Bliss model of synergism. Synergism was calculated using the Bliss Independence Model, which calculates a degree of synergy using the formula: S = (fA0/f00)(f0B/f00) − (fAB/f00), where fAB refers to bacterial
growth rate in the presence of the combined drugs at a concentration A, for one of the antibiotics, and
B for the ebselen; fA0 and f0B refer to the bacterial growth rates in the presence of antibiotics (or) ebselen
at a concentration of A and B, respectively; f00 refers to the bacterial growth rate in the absence of drugs;
and S corresponds to the degree of synergy, a parameter that determines a synergistic interaction for
positive values and an antagonistic interaction for negative ones. Growth rates at 12 hr are determined
and the degree of synergism was calculated as described before50.
Statistical analyses. Statistical analyses were assessed by Graph Pad Prism 6.0 (Graph Pad Software,

La Jolla, CA). P values were calculated by the two-tailed Student t test. P values of <0.05 were considered
as significant.
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